Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Prostate Cancer Clinical Trial

Official title:

A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00046826
• Other study ID #: CDR0000069081
• Secondary ID: NH-0139NCI-V01-1
• Status: Completed
• Phase: Phase 2
• First received: October 3, 2002
• Last updated: April 2, 2013
• Start date: September 2001
• Est. completion date: October 2009

Study information

• Verified date: January 2006
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine with thalidomide in treating patients who have prostate cancer previously treated with hormone therapy.

Description:

OBJECTIVES:

• Determine the objective response rate in patients with hormone-refractory prostate cancer treated with docetaxel, estramustine, and thalidomide.

• Determine the safety and toxicity of this regimen in these patients.

• Determine the efficacy of this regimen for pain control in these patients.

OUTLINE: Patients receive oral estramustine on days 1-3 and docetaxel IV over 1 hour on day 2 for 3 weeks. Treatment repeats every 4 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.

Patients also receive oral thalidomide once daily beginning on day 1 and continuing for 1 year in the absence of disease progression or unacceptable toxicity.

Patients are followed monthly until disease progression.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: October 2009
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the prostate

• Prior treatment with androgen ablation including:

• Orchiectomy OR

• Luteinizing hormone-releasing hormone (LHRH) therapy (e.g., leuprolide)

• Patients on leuprolide must continue to receive the drug

• Prior nonsteroidal antiandrogens (e.g., flutamide, bicalutamide, or nilutamide) required

• Metastatic disease with disease progression during androgen ablation, defined by at least 1 of the following:

• 2 consecutive increased prostate-specific antigen (PSA) levels measured at least 1 week apart

• More than 25% increase in bidimensionally measurable soft tissue metastases

• 20% increase in the sum of the baseline sum of longest diameter of measurable lesions

• Appearance of new lesions

• Appearance of new foci on a radionuclide bone scan

• PSA greater than 10 ng/dL

• Testosterone no greater than 50 ng/mL (castrate level)

• No CNS metastases

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• Karnofsky 70-100%

Life expectancy:

• More than 16 weeks

Hematopoietic:

• WBC greater than 3,500/mm3

• Absolute neutrophil count greater than 1,500/mm3

• Platelet count greater than 100,000/mm3

• Hemoglobin at least 8 g/dL

Hepatic:

• AST and/or ALT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase no greater than ULN OR

• Alkaline phosphatase no greater than 4 times ULN if AST/ALT no greater than ULN

• Bilirubin no greater than ULN

Renal:

• Creatinine less than 2.2 mg/dL

Cardiovascular:

• No myocardial infarction within the past 6 months

• No New York Heart Association class III or IV heart disease

• No history of arterial or venous thrombosis

• No cerebrovascular accident within the past year

Pulmonary:

• No history of pulmonary embolism

Other:

• Fertile patients must use effective contraception during and for 4 weeks after study

• No peripheral neuropathy grade 2 or greater

• No active infection

• No serious concurrent medical illness that would preclude study

• No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80

• No other prior or concurrent active malignancy within the past 2 years except non-melanoma skin cancers

• No other medical condition or reason that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for prostate cancer

Endocrine therapy:

• See Disease Characteristics

• At least 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) and continued evidence of disease progression (rising PSA)

• Prior steroids for prostate cancer allowed

• No concurrent steroids except for pre-medication for docetaxel

Radiotherapy:

• At least 4 weeks since prior radiotherapy

Surgery:

• See Disease Characteristics

Other:

• No concurrent herbal supplements to treat prostate cancer

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• docetaxel

• estramustine phosphate sodium

• thalidomide

Locations

Country	Name	City	State
United States	Whittingham Cancer Center at Norwalk Hospital	Norwalk	Connecticut
United States	Carl and Dorothy Bennett Cancer Center at Stamford Hospital	Stamford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Whittingham Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Frank RC, Coscia A, Versea L, et al.: Low dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HRPC): a phase II community based trial. [Abstract] J Clin Oncol 22 (Suppl

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate as measured by RECIST criteria and prostate-specific antigen (PSA) response 3 months, 6 months, and 1 year after treatment			No
Secondary	Safety and toxicity as measured by CTC toxicity grading at baseline and during every visit			Yes
Secondary	Effectiveness of taxotere, emcyt, and thalidomide in pain control as measured by the pain scale at baseline and during every visit			No